Alira Health Acquires BEPATIENT, A Step Forward in Humanizing Healthcare
28.10.2021 10:00:00 EEST | Business Wire | Press release
Alira Health (www.alirahealth.com), a leading technology-enabled services provider, announced that it has acquired BEPATIENT, a European healthcare technology company. BEPATIENT offers ‘real life’ digital patient data capture solutions for large pharmaceutical manufacturers, medical technology companies, associations, and public institutions and is one of the earliest VC-backed players in this space. The company provides clinical solutions for virtual trials and Real-World Evidence (RWE) as well as digital therapeutics for prevention and care management. This acquisition brings unparalleled technology and data capabilities to Alira Health’s full spectrum of patient-centric services that help providers, payers and suppliers uncover opportunity, accelerate innovation, and improve outcomes for patients.
“Every healthcare company says that they are patient-centric. Our acquisition of BEPATIENT demonstrates our dedication to patient-centricity and our investment in Real-World Evidence to power healthcare transformation,” said Benjamin Chambon, Co-founder and Chief Commercial Officer of Alira Health. “The future of healthcare is rooted in taking a patient-centric approach to every aspect of the industry. BEPATIENT is a linchpin in our strategy to transform and humanize healthcare. “
“BEPATIENT is a pioneer in the new clinical research and RWE world that puts patients at the heart of the healthcare ecosystem. We are excited to join Alira Health, a company that is equally passionate about the importance of patient empowerment and engagement in healthcare transformation.” said Frédéric Durand-Salmon, BEPATIENT’s CEO and Founder.
Frédéric Durand-Salmon will join Alira Health as VP of Clinical Digital Solutions. He will be one of Alira Health’s leaders in global software development and services initiatives that focus on synergies among the company’s Patient Engagement, Clinical, Global Market Access, RWE, and Management Consulting practices and BEPATIENT’s health platform.
About BEPATIENT:
BEPATIENT is a French company that has a comprehensive and modular core platform, enabling patients to be connected at home to Healthcare Professionals and to generate value-added Real-World Evidence (RWE) data. The BEPATIENT portfolio of solutions is structured around two activities: clinical research digitalization via direct-to-patient virtual trials technologies and digital therapeutics. BEPATIENT’s activities are mainly concentrated in EMEA and cover a wide range of therapeutic areas.
About Alira Health:
Alira Health is an international patient-centric and technology-enabled advisory firm on the frontlines of healthcare transformation. We provide a suite of integrated services designed to help healthcare and life science companies innovate and grow across their solutions lifecycle.
Alira Health was founded in 1999 and is based in Framingham, MA, U.S. Alira Health has offices in San Francisco, CA, U.S.; Paris, France; Barcelona, Spain; Munich, Germany; Milan, Bologna and Verona, Italy; and Basel and Geneva, Switzerland; and Cambridge, UK.
Learn more at https://www.alirahealth.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211028005109/en/
Contact information
Media Contact:
Susan Irving
Vice President of Global Marketing
Susan.irving@alirahealth.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 01:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
SLB Announces Date for Second-Quarter 2026 Results Conference Call26.5.2026 20:00:00 EEST | Press release
SLB (NYSE: SLB) will hold a conference call on July 24, 2026, to discuss the results for the second quarter ending June 30, 2026. The conference call is scheduled to begin at 9:30 a.m. U.S. Eastern time and a press release regarding the results will be issued at 7:00 a.m. U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 715-9871 within North America or +1 (646) 307-1963 outside of North America approximately 10 minutes prior to the start of the call and the access code is 3440360. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/157027565 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until July 31, 2026, and can be accessed by dialing +1 (800) 770-2030 within North America or +1
Alipay Launches Next-Generation AI Payment Infrastructure, Debuts AI Wallet and Token Pay to Power Agentic Economy26.5.2026 18:20:00 EEST | Press release
Alipay today introduced its full-stack AI payment solution to partners across industries, ranging from AI companies to traditional retailers, and debuted two new services — the world’s first AI Wallet and Token Pay — to support the agentic economy’s rapid growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526337824/en/ Alipay Unveils Next-generation AI Payment Infrastructure This launch extends Alipay's next-generation AI payment infrastructure, building on its consumer-facing product Alipay AI Pay and its business-facing AI payment processing product. “While the essence of commerce remains unchanged in the age of AI, the emergence of AI agents is reshaping everything. Drawing on 22 years of technological expertise and commercial know-how, Alipay is building a new generation of AI payment services to accelerate the growth of the agentic commerce ecosystem,” said Cyril Han, CEO of Ant Group. AI Wallet: Giving Users Vis
Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 202626.5.2026 18:00:00 EEST | Press release
Daiichi Sankyo Europe (DSE) is pleased to announce its extensive scientific presence at the European Atherosclerosis Society (EAS) Congress 2026. The presentation of 15 abstracts, comprising both clinical trial analyses and real-world evidence, underscores the company's sustained investment in cardiovascular health and its mission to care for every heartbeat. The 15-abstract showcase provides a comprehensive look at the role of bempedoic acid in lipid management. This includes post-hoc analyses in collaboration with Esperion Therapeutics from the Phase 3 CLEAR Outcomes trial exploring its impact on stroke and venous thromboembolism (VTE) incidence.5,6 There are also real-world findings from the MILOS registry, including a dedicated sub-analysis investigating the effectiveness of bempedoic acid across various background therapies.1,2,3,4 Results reinforce consistent effectiveness and safety profile of bempedoic acid across various EU countries and regardless of patients’ existing treatm
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 16:15:00 EEST | Press release
OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leading AI providers, including Anthropic, Google, OpenAI, xAI, and DeepSeek, among others. The platform is used by over 8 million global users, including AI-native startups and large enterprises,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom